December 4, 2023
OXFORD BIOMEDICA SIGNS AGREEMENT TO ACQUIRE ABL EUROPE FROM INSTITUT MERIEUX
Today, Oxford Biomedica announces the signing of a sale and purchase agreement with Institut Mérieux for the acquisition of ABL Europe.
The acquisition of ABL Europe will consolidate Oxford Biomedica’s operations into a global pure-play CDMO in the cell and gene therapy space. It will broaden the Company’s international presence by establishing a footprint within the European Union through facilities located in Lyon and Strasbourg, France. In addition, the acquisition will increase Oxford Biomedica’s capacity in process and analytical development and early-stage manufacturing and address increased client demand for process development.
Click here to read the full press release.